Just let them. It will be your opportunity to buy more. Now I know results were blinded when we saw the slides at conference. But I highly doubt the placebo drug reduced the scarring, and the reduction was pretty huge. If we get the unblinded data and it's even better. This stock shoots to the moon!
What an opportunity to buy this stock at .26 cents or if you bought it at .08 cents. If successful through trials just RXI-109 alone is valued in the billions. Plus if you look at Regeneron they targeted dry macular degeneration but haven't been able to target wed AMD. RXII has the ability with its platform to go after Wet AMD which is a huge market. Just buy your shares and ignore the day trading of it, and watch over the years as you surge to new heights.
I received some free RXII shares from the Gale spin-off. I have conducted much DD on RXII.
I have been buying a good number of RXII shares in the last 14 months. The weighted average of my RXII shares is around 10 cents. I plan to add more RXII shares in the near future. So far, I have not sold a single RXII share.
If you go back in history on messages on this board, I am one of the first who wrote about the potential of RXII.
I have condifence on my DD and I am an investor, not a speuclator or day-trader at all. I plan to hold my RXII shares for at least 2 to 3 years.
Yes! I am a firm believer that RXII will become a major biotech company and yes, its share price will reach $40 in 2 to 3 years!
It is good that we have knowledgeable and positive contributors (Rmsacc inculded) on this board.
I agree w/ biopharmaniac. It is impossible for a placebo to cause a physiological response. This drug does not reduce migrane headaches which is subjective to the patient. There seems to be a better response when a patient is treated w/ one of the drugs (API or placebo). My guess is that the drug substance is causing the reduction in scarring (& time) so if I was a betting man, I would long this stock. Oh wait, I am and I did.
I do appreciate some of the market analysis on this board as I am more of a science guy leaning the numbers. Regardless of what the potential is (I see $20- 40 / share long term), there is much more upside than down. This thing has a lot of room to grow & not much room to drop. So, I am sticking w/ it very long term. I do agree that it will get volatile as it becomes more expensive; but, these spec biotechs are not for the faint of heart.